[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572032":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":26,"centralContacts":30,"locations":37,"responsibleParty":54,"collaborators":10,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":10,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":70,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":10,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Qilu Hospital of Shandong University","OTHER",[8,13],{"label":9,"type":10,"description":10,"interventionNames":11},"ICI plus chemotherapy",null,[12],"Drug: ICI plus Chemothearpy",{"label":14,"type":10,"description":10,"interventionNames":15},"Chemotherapy",[16],"Drug: Chemotherapy",[18,23],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DRUG","ICI plus Chemothearpy","This intervention involves the administration of immune checkpoint inhibitors (ICIs) in combination with standard chemotherapy.",[9],{"type":19,"name":14,"description":24,"armGroupLabels":25,"otherNames":10},"This intervention involves the administration of standard chemotherapy alone.",[14],[27],{"name":28,"affiliation":5,"role":29},"Lian Liu, MD","PRINCIPAL_INVESTIGATOR",[31,35],{"name":28,"role":32,"phone":33,"phoneExt":10,"email":34},"CONTACT","0531-82169851","tounao@126.com",{"name":36,"role":32,"phone":33,"phoneExt":10,"email":10},"Song Li, MD",[38],{"facility":5,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Jinan","Shandong","250012","China","CN",{"type":46,"coordinates":47},"Point",[48,49],116.99722,36.66833,{"lat":49,"lon":48},[52,53],{"name":28,"role":32,"phone":33,"phoneExt":10,"email":34},{"name":36,"role":32,"phone":33,"phoneExt":10,"email":10},{"type":29,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Lian Liu, MD, PHD","Professor, Chief Physician","100572032","first-line-and-neoadjuvant-immunotherapy-for-gastric-cancer-100572032",false,"NCT06727981","First-Line and Neoadjuvant Immunotherapy for Gastric Cancer","Prospective Cohort Study on the Efficacy, Adverse Effects, and Biomarkers of First-Line\u002FNeoadjuvant Therapy With Immune Checkpoint Inhibitors Combined With Chemotherapy in Advanced Gastric Cancer","Inclusion Criteria:\n\n1. Age 18 years old or above\n2. Patients with advanced gastric cancer or locally advanced gastric cancer\n3. Have not received any previous anti-tumor therapy\n4. Patients expected to receive immunotherapy for first-line or neoadjuvant therapy\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n6. Adequate organ function\n\nExclusion Criteria:\n\n1. Patients with contraindications to immunotherapy\n2. Have received anti-tumor treatments such as immunotherapy and chemotherapy\n3. Have a history of active immune deficiency or autoimmune diseases, including HIV positive test, or have other acquired or congenital immune deficiency diseases, or have a history of organ transplantation or autoimmune diseases\n4. Severe chronic or active infection requires systemic antibacterial, antifungal, or antiviral treatment, including tuberculosis infection. Have a history of active tuberculosis infection ≥ 1 year before recruitment should also be excluded, unless proved has been completed appropriate treatment\n5. History of allogeneic stem cell transplantation or organ transplantation","ALL","18 Years","100 Years",{"count":68,"type":69},500,"ESTIMATED","1 Year","OBSERVATIONAL","This prospective observational study aims to evaluate the efficacy and safety of immune checkpoint inhibitors as first-line and neoadjuvant therapy for advanced gastric cancer, while also investigating relevant biomarkers to better understand their role in immunotherapy outcomes",[74,75],"Advanced Gastric Cancer","Locally Advanced Gastric Carcinoma","2024-12-10",{"date":78,"type":79},"2024-12-11","ACTUAL",{"date":81,"type":79},"2022-01-15",{"date":83,"type":69},"2028-01-15",{"name":5,"class":6},1]